Report Detail
Global Hepatic Encephalopathy (HE) Therapeutics Market Insights, Forecast to 2025
- RnM2717054 |
- 14 June, 2019 |
- Global |
- 116 Pages |
- QYResearch |
- Pharma & Healthcare
HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
The most commonly used therapeutics to treat HE are lactulose and rifaximin. Researchers are also developing treatments that targets ammonia production and removal. For instance, AST-120 is under investigation and targets gut-derived toxins for liver cirrhosis. It can also be used to treat HE. The progression and development of HE sometimes depends on factors such as inflammation. This is compelling researchers to introduce various treatments that targets inflammation. Some of the most recent approaches to treat HE includes probiotics, albumin administration, and dialysis. Such emergence of novel hepatic encephalopathy treatment targets is identified as one of the key trends that will stimulate growth in the hepatic encephalopathy (HE) therapeutics market during the forecasted period.
The global Hepatic Encephalopathy (HE) Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hepatic Encephalopathy (HE) Therapeutics market based on company, product type, end user and key regions.
This report studies the global market size of Hepatic Encephalopathy (HE) Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hepatic Encephalopathy (HE) Therapeutics in these regions.
This research report categorizes the global Hepatic Encephalopathy (HE) Therapeutics market by top players/brands, region, type and end user. This report also studies the global Hepatic Encephalopathy (HE) Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
ASKA Pharmaceutical
COSMO PHARMACEUTICALS
Mallinckrodt
Valeant
Market size by Product
Lactulose
Rifaximin
Neomycin
Probiotics
Thiamine
Market size by End User
Acute Liver Failure
Portal Systemic Bypass Without Liver Disease
Liver Cirrhosis
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Hepatic Encephalopathy (HE) Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hepatic Encephalopathy (HE) Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hepatic Encephalopathy (HE) Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hepatic Encephalopathy (HE) Therapeutics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Hepatic Encephalopathy (HE) Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hepatic Encephalopathy (HE) Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Hepatic Encephalopathy (HE) Therapeutics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Product
- 1.4.2 Lactulose
- 1.4.3 Rifaximin
- 1.4.4 Neomycin
- 1.4.5 Probiotics
- 1.4.6 Thiamine
- 1.5 Market by End User
- 1.5.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by End User
- 1.5.2 Acute Liver Failure
- 1.5.3 Portal Systemic Bypass Without Liver Disease
- 1.5.4 Liver Cirrhosis
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size
- 2.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue 2014-2025
- 2.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales 2014-2025
- 2.2 Hepatic Encephalopathy (HE) Therapeutics Growth Rate by Regions
- 2.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales by Regions
- 2.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Hepatic Encephalopathy (HE) Therapeutics Sales by Manufacturers
- 3.1.1 Hepatic Encephalopathy (HE) Therapeutics Sales by Manufacturers
- 3.1.2 Hepatic Encephalopathy (HE) Therapeutics Sales Market Share by Manufacturers
- 3.1.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Hepatic Encephalopathy (HE) Therapeutics Revenue by Manufacturers
- 3.2.1 Hepatic Encephalopathy (HE) Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.3 Hepatic Encephalopathy (HE) Therapeutics Price by Manufacturers
- 3.4 Hepatic Encephalopathy (HE) Therapeutics Manufacturing Base Distribution, Product Types
- 3.4.1 Hepatic Encephalopathy (HE) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Hepatic Encephalopathy (HE) Therapeutics Product Type
- 3.4.3 Date of International Manufacturers Enter into Hepatic Encephalopathy (HE) Therapeutics Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales by Product
- 4.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Product
- 4.3 Hepatic Encephalopathy (HE) Therapeutics Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by End User
6 North America
- 6.1 North America Hepatic Encephalopathy (HE) Therapeutics by Countries
- 6.1.1 North America Hepatic Encephalopathy (HE) Therapeutics Sales by Countries
- 6.1.2 North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Hepatic Encephalopathy (HE) Therapeutics by Product
- 6.3 North America Hepatic Encephalopathy (HE) Therapeutics by End User
7 Europe
- 7.1 Europe Hepatic Encephalopathy (HE) Therapeutics by Countries
- 7.1.1 Europe Hepatic Encephalopathy (HE) Therapeutics Sales by Countries
- 7.1.2 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Hepatic Encephalopathy (HE) Therapeutics by Product
- 7.3 Europe Hepatic Encephalopathy (HE) Therapeutics by End User
8 Asia Pacific
- 8.1 Asia Pacific Hepatic Encephalopathy (HE) Therapeutics by Countries
- 8.1.1 Asia Pacific Hepatic Encephalopathy (HE) Therapeutics Sales by Countries
- 8.1.2 Asia Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Hepatic Encephalopathy (HE) Therapeutics by Product
- 8.3 Asia Pacific Hepatic Encephalopathy (HE) Therapeutics by End User
9 Central & South America
- 9.1 Central & South America Hepatic Encephalopathy (HE) Therapeutics by Countries
- 9.1.1 Central & South America Hepatic Encephalopathy (HE) Therapeutics Sales by Countries
- 9.1.2 Central & South America Hepatic Encephalopathy (HE) Therapeutics Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Hepatic Encephalopathy (HE) Therapeutics by Product
- 9.3 Central & South America Hepatic Encephalopathy (HE) Therapeutics by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics by Countries
- 10.1.1 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Sales by Countries
- 10.1.2 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics by Product
- 10.3 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics by End User
11 Company Profiles
- 11.1 ASKA Pharmaceutical
- 11.1.1 ASKA Pharmaceutical Company Details
- 11.1.2 Company Business Overview
- 11.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Products Offered
- 11.1.5 ASKA Pharmaceutical Recent Development
- 11.2 COSMO PHARMACEUTICALS
- 11.2.1 COSMO PHARMACEUTICALS Company Details
- 11.2.2 Company Business Overview
- 11.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Products Offered
- 11.2.5 COSMO PHARMACEUTICALS Recent Development
- 11.3 Mallinckrodt
- 11.3.1 Mallinckrodt Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Products Offered
- 11.3.5 Mallinckrodt Recent Development
- 11.4 Valeant
- 11.4.1 Valeant Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Valeant Hepatic Encephalopathy (HE) Therapeutics Products Offered
- 11.4.5 Valeant Recent Development
12 Future Forecast
- 12.1 Hepatic Encephalopathy (HE) Therapeutics Market Forecast by Regions
- 12.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Regions 2019-2025
- 12.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Forecast by Regions 2019-2025
- 12.2 Hepatic Encephalopathy (HE) Therapeutics Market Forecast by Product
- 12.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Product 2019-2025
- 12.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Forecast by Product 2019-2025
- 12.3 Hepatic Encephalopathy (HE) Therapeutics Market Forecast by End User
- 12.4 North America Hepatic Encephalopathy (HE) Therapeutics Forecast
- 12.5 Europe Hepatic Encephalopathy (HE) Therapeutics Forecast
- 12.6 Asia Pacific Hepatic Encephalopathy (HE) Therapeutics Forecast
- 12.7 Central & South America Hepatic Encephalopathy (HE) Therapeutics Forecast
- 12.8 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Hepatic Encephalopathy (HE) Therapeutics Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Hepatic Encephalopathy (HE) Therapeutics . Industry analysis & Market Report on Hepatic Encephalopathy (HE) Therapeutics is a syndicated market report, published as Global Hepatic Encephalopathy (HE) Therapeutics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Hepatic Encephalopathy (HE) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
